Topic 3: OUD Treatment in Specific Settings

Pharmacy-based initiative in the treatment of Opioid Use Disorder and Harm Reduction

Activity Details
  • Credit Amounts:
    • CME: 1.00
    • CPE: 1.00
    • ASWB ACE: 1.00
    • CNE: 1.00
  • Cost: Free
  • Release: Apr 25, 2024
  • Expires: Apr 24, 2026
  • Estimated Time to Complete:
    1 Hour(s)
  • Average User Rating:
    (4 Ratings)

Pharmacy-based Initiative in the Treatment of Opioid Use Disorder and Harm Reduction enduring module is a recording from the live Regularly Scheduled Series dated September 14, 2023. If you claimed credit for this session at the live meeting, you should not claim credit for this module.


Traci Green Traci Green, PhD, MSc
Adjunct Associate Professor
Warren Alpert School of Medicine
Brown University
Center of Biomedical Research Excellence (COBRE) on Opioids and Overdose
Rhode Island Hospital
Waltham, Massachusetts

Needs Statement

Pharmacy-based care normalizes receipt of medication for opioid use disorder (MOUD), which may increase treatment engagement and reduce stigma and overdose risk.  Most states allow pharmacists to collaborate with prescribers, confer prescriptive authority, or have other mechanisms to expand the scope of practice for pharmacists.  To meet the widening treatment gap for MOUD and equitable and accessible MOUD, pharmacy care models are needed. New data suggest they are possible, effective, and safe.

Target Audience

Peer Support specialists, Care Navigators, Physicians, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, Social


Upon completion of this activity, participants will be able to:

  1. Describe the rationale for addressing addiction care in community pharmacies and identify key characteristics of the pharmacy-based addiction care model.

  2. Discuss the findings of the randomized trial comparing pharmacy-based addiction care to usual, clinic care models including primary outcomes and study limitations.
  3. List facilitators and barriers of implementing and sustaining the pharmacy care model to address the opioid crisis.
  4. Discuss notable state and national actions to expand scope of practice for pharmacists and pharmacy staff
  5. Describe opportunities for continued expansion of pharmacist-delivered clinical services.


In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0923-H1.5-UKHC/Sept23

IPE Competencies

  • Values/Ethics for Interprofessional Practice
  • Roles/ Responsibilities
  • Interprofessional Communication
  • Teams and Teamwork

This knowledge-based activity will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.00 clinical continuing education credit.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation


In collaboration with UK Substance Use Research Priority Area.